Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LNG Energy Announces Signing of Hydrocarbon Productive Participation Contracts (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News TG Therapeutics Inc TGTX

Healthcare Biotechnology
TG Therapeutics, Inc. is a fully integrated, commercial stage, biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. Its clinical drug candidates include Ublituximab (anti-CD20 mAb), TG-1701 (BTK inhibitor) and TG-1801 (anti-CD47/CD19 bispecific mAb). BRIUMVI is an anti-CD20 monoclonal antibody for the... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:TGTX)

TG Therapeutics Announces Additional Data Presentations for BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting

GlobeNewswire 6 days ago

TG Therapeutics Awarded National Contract by the Department of Veterans Affairs for BRIUMVI as the Preferred Anti-CD20 for Relapsing Forms of Multiple Sclerosis

GlobeNewswire 6 days ago

TG Therapeutics Announces Presentation of Data for BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting

GlobeNewswire 9 days ago

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against TG Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm

Accesswire March 22, 2024

TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting

GlobeNewswire March 8, 2024

TG Therapeutics Announces Presentation of Data for BRIUMVI® in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum

GlobeNewswire March 1, 2024

TG Therapeutics Provides Business Update and Reports Fourth Quarter and Year-End 2023 Financial Results

GlobeNewswire February 28, 2024

TG Therapeutics Announces Issuance of Additional Patents for BRIUMVI® (ublituximab-xiiy)

GlobeNewswire February 27, 2024

TG Therapeutics Announces European Launch of BRIUMVI® (ublituximab-xiiy)

GlobeNewswire February 26, 2024
View More News ››

Opinion & Analysis (NDAQ:TGTX)

Let volatility power your micro-cap biotechs

The Life Sciences Report April 28, 2016
View More Opinion ››

Bullboard Posts (NDAQ:TGTX)

therapeutic gift

Check out this amazing investment opportunity: I just bought shares of XYZ company at $10, and sold a call option with a strike price of ...
stockpsycho - May 10, 2023

Now approved!

That's my Christmas gift to myself. 
hoffbag - December 28, 2022

What a Christmas gift

Got to love gifts like this Bot stock $8.25 Sold Jan 2023 $10 Call for $2 If FDA comes thru and SP is above $10 in less than 30 days...
Ogopogo007 - December 23, 2022

Any hope of recovery?

The stock is heading sout with 'strong buy' recommendation.  Where is the disconnect?
yellowtab - November 3, 2017
View more Bullboard ››

Prairie Provident Resources Inc

Prairie Provident Resources Inc

Prairie Provident Resources Inc. is a Canada-based oil and natural gas exploration company. The Company is engaged in the ...
View More »